Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + HIFU + Chemo in HR+/HER2- Breast Cancer
NCT06470633Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2024
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab in breast cancer, sponsored by Jiangsu Provincial People's Hospital. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06470633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06470633.